Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5‑aza‑2'‑deoxycytosine with potential therapeutic significance in Burkitt's lymphoma

Gao,Xian‑Zheng; Zhao,Wu‑Gan; Wang,Guan‑Nan; Cui,Mei‑Ying; Zhang,Yang‑Rui; Li,Wen‑Cai

doi:10.3892/mmr.2015.4640

Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5‑aza‑2'‑deoxycytosine with potential therapeutic significance in Burkitt's lymphoma

Authors:
- Xian‑Zheng Gao
- Wu‑Gan Zhao
- Guan‑Nan Wang
- Mei‑Ying Cui
- Yang‑Rui Zhang
- Wen‑Cai Li
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
Published online on: December 4, 2015 https://doi.org/10.3892/mmr.2015.4640
Pages: 1269-1274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epigenetic gene silencing due to promoter methylation is observed in human neoplasia, including lymphoma and certain cancer types. One important target for gene methylation analysis in non‑Hodgkin lymphoma (NHL) is inhibitor of DNA binding 4 (ID4). The present study aimed to investigate the gene methylation status of ID4, the expression of ID4 protein and the effect of demethylating agent 5‑aza‑2'‑deoxycytosine (CdR) in the Raji human Burkitt's lymphoma cell line in vitro. Following assessment of the inhibition of Raji cell growth by various concentrations of CdR, the effects of CdR on the expression of ID4 protein were assessed using the immunocytochemical streptavidin‑peroxidase method and semi‑quantitative analysis, while apoptosis and cell cycle were determined by flow cytometry. The ID4 gene methylation status of Raji cells was tested using methylation‑specific polymerase chain reaction analysis. ID4 was methylated and its protein expression was low in the control group, while ID4 was partly or completely demethylated and its protein expression was upregulated in Raji cells treated with CdR. In addition, CdR induced apoptosis and cell cycle arrest in Raji cells in a dose‑ and time‑dependent manner. These results demonstrated that ID4 is hypermethylated and its protein expression is low in Burkitt's lymphoma cells, while CdR reversed the abnormal DNA methylation and induced re‑expression of ID4 protein. Hypermethylation of ID4 promotes the proliferation of Burkitt's lymphoma cells; ID4 may function as a tumor suppressor and can be targeted with demethylating compounds such as CdR for the treatment of Burkitt's lymphoma.

View Figures

View References

1	Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, et al: A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol. 31:4140–4147. 2013. View Article : Google Scholar : PubMed/NCBI
2	Esteller M: Dormant hypermethylated tumour suppressor genes: Questions and answers. J Pathol. 205:172–180. 2005. View Article : Google Scholar : PubMed/NCBI
3	Sato T, Arai E, Kohno T, Tsuta K, Watanabe S, Soejima K, Betsuyaku T and Kanai Y: DNA methylation profiles at precancerous stages associated with recurrence of lung adenocarcinoma. PLoS One. 8:594442013. View Article : Google Scholar
4	Guillaumet-Adkins A, Richter J, Odero MD, Sandoval J, Agirre X, Catala A, Esteller M, Prósper F, Calasanz MJ, Buño I, et al: Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels. J Hematol Oncol. 7:42014. View Article : Google Scholar : PubMed/NCBI
5	Zebedee Z and Hara E: Id proteins in cell cycle control and cellular senescence. Oncogene. 20:8317–8325. 2001. View Article : Google Scholar
6	Rivera R and Murre C: The regulation and function of the Id proteins in lymphocyte development. Oncogene. 20:8308–8316. 2001. View Article : Google Scholar
7	Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, et al: Global assessment of promoter methylation in a mouse model of cancer identifies Id4 as a putative tumor-suppressor gene in human leukemia. Nat Genet. 37:265–274. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wilson JW, Deed RW, Inoue T, Balzi M, Becciolini A, Faraoni P, Potten CS and Norton JD: Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. Cancer Res. 61:8803–8810. 2001.PubMed/NCBI
9	Kuzontkoski PM, Mulligan-Kehoe MJ, Harris BT and Israel MA: Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels. Oncogene. 29:3793–3802. 2010. View Article : Google Scholar : PubMed/NCBI
10	Zeng W, Rushing EJ, Hartmann DP and Azumi N: Increased inhibitor of differentiation 4 (id4) expression in glioblastoma: A tissue microarray study. J Cancer. 1:1–5. 2010. View Article : Google Scholar : PubMed/NCBI
11	Arnold JM, Mok SC, Purdie D and Chenevix-Trench G: Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas. Br J Cancer. 84:352–359. 2001. View Article : Google Scholar : PubMed/NCBI
12	Deleu S, Savonet V, Behrends J, Dumont JE and Maenhaut C: Study of gene expression in thyrotropin-stimulated thyroid cells by cDNA expression array: ID3 transcription modulating factor as an early response protein and tumor marker in thyroid carcinomas. Exp Cell Res. 279:62–70. 2002. View Article : Google Scholar : PubMed/NCBI
13	Lasorella A, Uo T and Iavarone A: Id proteins at the cross-road of development and cancer. Oncogene. 20:8326–8333. 2001. View Article : Google Scholar
14	Hagiwara K, Nagai H, Li Y, Ohashi H, Hotta T and Saito H: Frequent DNA methylation but not mutation of the ID4 gene in malignant lymphoma. J Clin Exp Hematop. 47:15–18. 2007. View Article : Google Scholar : PubMed/NCBI
15	Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE and Hoon DS: Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene. 24:4721–4727. 2005. View Article : Google Scholar : PubMed/NCBI
16	Cen J, Shen J, Wang X, Kang H, Wang L, Sun L, Li Y and Yu L: Association between lymphoma prognosis and aberrant methylation of ID4 and ZO-1 in bone marrow and paraffin-embedded lymphoma tissues of treatment-naive patients. Oncol Rep. 30:455–461. 2013.PubMed/NCBI
17	Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR, Clouston AD, Gotley DC, et al: Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer. 7:752008. View Article : Google Scholar : PubMed/NCBI
18	Noetzel E, Veeck J, Horn F, Hartmann A, Knüchel R and Dahl E: Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer. Pathologe. 29(Suppl 2): S319–S327. 2008.In German. View Article : Google Scholar
19	Yang Q, Shan L, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Umemura T, Mori I, Sakurai T and Kakudo K: 5-aza-2′-deoxycytidine induces retinoic acid receptor beta 2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anticancer Res. 22:2753–2756. 2002.
20	Wang H, Wang XQ, Xu XP and Lin GW: ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leuk Res. 34:598–604. 2010. View Article : Google Scholar
21	Rüter B, Wijermans PW and Lübbert M: DNA methylation as a therapeutic target in hematologic disorders: Recent results in older patients with myelodysplasia and acute myeloid leukemia. Int J Hematol. 80:128–135. 2004. View Article : Google Scholar : PubMed/NCBI
22	Umetani N, Takeuchi H, Fujimoto A, Shinozaki M, Bilchik AJ and Hoon DS: Epigenetic inactivation of Id4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res. 10:7475–7483. 2004. View Article : Google Scholar : PubMed/NCBI
23	Vinarskaja A, Goering W, Ingenwerth M and Schulz WA: ID4 is frequently downregulated and partially hypermethylated in prostate cancer. World J Urol. 30:319–325. 2012. View Article : Google Scholar
24	Xu RR, Liu F, Cui X, Zhang XW and Wang Y: ID4 promoter methylation in acute myeloid leukemia. J Exp Hematol. 19:582–584. 2011.In Chinese.
25	Dell'Orso S, Ganci F, Strano S, Blandino G and Fontemaggi G: ID4: A new player in the cancer arena. Oncotarget. 1:48–58. 2010. View Article : Google Scholar
26	Chan AS, Tsui WY, Chen X, Chu KM, Chan TL, Chan AS, Li R, So S, Yuen ST and Leung SY: Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma. Oncogene. 22:6946–6953. 2003. View Article : Google Scholar : PubMed/NCBI
27	Qu F, Zhao CH, Diao YQ, Zhu XL, Chen J, Li M, Liu CP, Jiang L and Jin J: Methylation of Id4 gene and inhibitive effect of arsenic trioxide on it in Raji cells. Clin J Hematol. 31:821–825. 2010.In Chinese.
28	Vandeputte DA, Troost D, Leenstra S, Ijlst-Keizers H, Ramkema M, Bosch DA, Baas F, Das NK and Aronica E: Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia. 38:329–338. 2002. View Article : Google Scholar : PubMed/NCBI